AstraZeneca: revenue and profit continue to grow
(CercleFinance.com) - AstraZeneca said its revenue and profit continued to grow in the first half of the year, helped by successful launches of new medicines.
The Anglo-Swedish drugmaker said core EPS grew by 24% to 2.01 dollars in the six months to 30 June, with revenue rising 12% to 12.6 billion dollars.
The sales of new medicines such as lung cancer drugs Tagrisso and Imfinzi and the ovarian cancer drug Lynparza rose by 42% to 6.4 billion dollars, the company said.
AstraZeneca maintained its full-year guidance, expecting high single-digit to low double-digit growth in revenue, along with mid- to high-teen percentage growth in core EPS.
The London-listed shares were up over 3% on this news.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Anglo-Swedish drugmaker said core EPS grew by 24% to 2.01 dollars in the six months to 30 June, with revenue rising 12% to 12.6 billion dollars.
The sales of new medicines such as lung cancer drugs Tagrisso and Imfinzi and the ovarian cancer drug Lynparza rose by 42% to 6.4 billion dollars, the company said.
AstraZeneca maintained its full-year guidance, expecting high single-digit to low double-digit growth in revenue, along with mid- to high-teen percentage growth in core EPS.
The London-listed shares were up over 3% on this news.
Copyright (c) 2020 CercleFinance.com. All rights reserved.